SCHEMBL24197052

SCHEMBL24197052

CC(C)N1CCC(n2nc(-c3ccc(Oc4ccccc4)c(F)c3)c3c(N)ncnc32)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 12/20 0.63
▸ NUDT14 O95848 1/20 0.63
▸ NUDT5 Q9UKK9 1/20 0.63
▸ LCK P06239 3/20 0.59
▸ LYN P07948 1/20 0.59
▸ SRC P12931 6/20 0.57
▸ KDR P35968 6/20 0.57
▸ TEK Q02763 1/20 0.57
▸ EGFR P00533 8/20 0.54
▸ PIK3CD O00329 6/20 0.54
▸ PIK3CA P42336 6/20 0.54
▸ PIK3CB P42338 6/20 0.54
▸ PIK3CG P48736 6/20 0.54
▸ PRKDC P78527 6/20 0.54
▸ ABL1 P00519 5/20 0.54
▸ HCK P08631 5/20 0.54
▸ MTOR P42345 5/20 0.54
▸ EPHB4 P54760 5/20 0.54
▸ PI4KB Q9UBF8 4/20 0.54
▸ ERBB3 P21860 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197166 0.90 BTK (0.65) BTKNUDT14NUDT5LCKLYN
SCHEMBL25933023 0.88 BTK (0.63) BTKNUDT14NUDT5LCKLYN
SCHEMBL24827785 0.88 BTK (0.80) BTKNUDT14NUDT5LCKLYN
SCHEMBL24196618 0.86 BTK (0.63) BTKNUDT14NUDT5LCKLYN
SCHEMBL30416266 0.86 BTK (0.63) BTKNUDT14NUDT5LCKLYN
SCHEMBL24197234 0.86 BTK (0.59) BTKNUDT14NUDT5LCKLYN
SCHEMBL24196632 0.85 SRC (0.60) BTKNUDT14NUDT5LCKLYN
SCHEMBL24196636 0.85 SRC (0.60) BTKNUDT14NUDT5LCKLYN
SCHEMBL6434916 0.84 BTK (0.76) BTKNUDT14NUDT5LCKLYN
SCHEMBL24197054 0.84 BTK (0.62) BTKNUDT14NUDT5LCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed
EP-4180432-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 — — EP disclosed
WO-2022007824-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR 四川海思科制药有限公司 2022-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885NUDT14 3438/4885NUDT5 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback